

Nicole Skoetz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9452725/publications.pdf>

Version: 2024-02-01

108
papers

7,591
citations

159525

30
h-index

64755

79
g-index

125
all docs

125
docs citations

125
times ranked

13889
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. <i>BMJ</i> , The, 2020, 369, m1328.	3.0	2,134
2	GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. <i>Journal of Clinical Epidemiology</i> , 2020, 119, 126-135.	2.4	490
3	Adverse effects of biologics: a network meta-analysis and Cochrane overview. <i>The Cochrane Library</i> , 2016, 2016, CD008794.	1.5	481
4	Living systematic review: 1. Introduction—the why, what, when, and how. <i>Journal of Clinical Epidemiology</i> , 2017, 91, 23-30.	2.4	406
5	Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2007, 99, 706-714.	3.0	344
6	Living systematic reviews: 2. Combining human and machine effort. <i>Journal of Clinical Epidemiology</i> , 2017, 91, 31-37.	2.4	246
7	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. <i>The Cochrane Library</i> , 2020, 7, CD013600.	1.5	235
8	Living systematic reviews: 4. Living guideline recommendations. <i>Journal of Clinical Epidemiology</i> , 2017, 91, 47-53.	2.4	184
9	Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 914-918.	1.3	169
10	Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. <i>Lancet Oncology</i> , The, 2013, 14, 943-952.	5.1	158
11	Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. <i>Lancet</i> , The, 2015, 385, 1418-1427.	6.3	154
12	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. <i>The Cochrane Library</i> , 2020, 5, CD013600.	1.5	133
13	Systemic corticosteroids for the treatment of COVID-19. <i>The Cochrane Library</i> , 2021, 2021, CD014963.	1.5	119
14	SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. <i>The Cochrane Library</i> , 2021, 2021, CD013825.	1.5	114
15	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. <i>The Cochrane Library</i> , 2021, 2021, CD013600.	1.5	109
16	Living systematic reviews: 3. Statistical methods for updating meta-analyses. <i>Journal of Clinical Epidemiology</i> , 2017, 91, 38-46.	2.4	102
17	Ivermectin for preventing and treating COVID-19. <i>The Cochrane Library</i> , 2021, 2021, CD015017.	1.5	101
18	Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. <i>Haematologica</i> , 2010, 95, 494-500.	1.7	93

#	ARTICLE	IF	CITATIONS
19	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. The Cochrane Library, 2020, 10, CD013600.	1.5	91
20	Vitamin D supplementation for the treatment of COVID-19: a living systematic review. The Cochrane Library, 2021, 2021, CD015043.	1.5	78
21	European Respiratory Society guideline on non-CPAP therapies for obstructive sleep apnoea. European Respiratory Review, 2021, 30, 210200.	3.0	75
22	Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. The Cochrane Library, 2014, 2014, CD010189.	1.5	73
23	Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults—a systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2015, 94, 179-188.	2.0	65
24	Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. The Cochrane Library, 2010, 2010, CD003805.	1.5	62
25	High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. The Cochrane Library, 2013, , CD009411.	1.5	57
26	Antibiotics for the treatment of COVID-19. The Cochrane Library, 2022, 2022, CD015025.	1.5	49
27	Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. The Cochrane Library, 2017, 5, CD007941.	1.5	47
28	GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and Evidence Profiles. Journal of Clinical Epidemiology, 2020, 118, 124-131.	2.4	44
29	Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma. , 2011, , CD007110.		43
30	Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. , 2011, , CD007941.		39
31	Colchicine for the treatment of COVID-19. The Cochrane Library, 2021, 2021, CD015045.	1.5	36
32	Inhaled corticosteroids for the treatment of COVID-19. The Cochrane Library, 2022, 2022, CD015125.	1.5	34
33	Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis—a systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2013, 88, 178-186.	2.0	33
34	Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. The Cochrane Library, 2012, 11, CD008079.	1.5	32
35	Allogeneic stem cell transplantation for advanced primary cutaneous T-cell lymphoma: A systematic review. Critical Reviews in Oncology/Hematology, 2013, 85, 21-31.	2.0	31
36	Key summary of German national treatment guidance for hospitalized COVID-19 patients. Infection, 2022, 50, 93-106.	2.3	30

#	ARTICLE	IF	CITATIONS
37	High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: A systematic review with meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 1-10.	2.0	29
38	Developing trustworthy recommendations as part of an urgent response (1â€“2 weeks): a GRADE concept paper. <i>Journal of Clinical Epidemiology</i> , 2021, 129, 1-11.	2.4	29
39	Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. <i>The Cochrane Library</i> , 2012, , CD009159.	1.5	28
40	Alemtuzumab for patients with chronic lymphocytic leukaemia. <i>The Cochrane Library</i> , 2012, , CD008078.	1.5	26
41	Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma. <i>The Cochrane Library</i> , 2015, 1, CD010533.	1.5	25
42	Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association. <i>Lancet Haematology</i> , 2022, 9, e361-e373.	2.2	25
43	High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults. <i>The Cochrane Library</i> , 2012, 1, CD007678.	1.5	24
44	Methodological challenges for living systematic reviews conducted during the COVID-19 pandemic: A concept paper. <i>Journal of Clinical Epidemiology</i> , 2022, 141, 82-89.	2.4	24
45	Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis. <i>The Cochrane Library</i> , 2020, 2020, CD012022.	1.5	23
46	Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	23
47	Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. <i>The Cochrane Library</i> , 2020, 2020, CD013020.	1.5	22
48	Janus kinase inhibitors for the treatment of COVID-19. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	22
49	Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. <i>The Cochrane Library</i> , 2020, 2020, .	1.5	21
50	â€œThe system has to be health literate, tooâ€• perspectives among healthcare professionals on health literacy in transcultural treatment settings. <i>BMC Health Services Research</i> , 2021, 21, 716.	0.9	21
51	Hodgkin Lymphoma in Adults. <i>Deutsches A&#x0308;rztblatt International</i> , 2018, 115, 535-540.	0.6	21
52	Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. <i>The Cochrane Library</i> , 2022, 2022, CD012775.	1.5	21
53	Fifteenth Biannual Report of the Cochrane Haematological Malignancies Groupâ€“Focus on Non-Hodgkin's Lymphoma. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1159-1170.	3.0	20
54	Yoga in addition to standard care for patients with haematological malignancies. <i>The Cochrane Library</i> , 2014, , CD010146.	1.5	20

#	ARTICLE	IF	CITATIONS
55	SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. The Cochrane Library, 2022, 2022, .	1.5	20
56	Ivermectin for preventing and treating COVID-19. The Cochrane Library, 2024, 2024, .	1.5	19
57	Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL). The Cochrane Library, 2012, 11, CD009355.	1.5	18
58	Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. The Cochrane Library, 2020, 2020, CD012643.	1.5	18
59	Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. The Cochrane Library, 2021, 2021, CD013365.	1.5	18
60	Assessment of prostate-specific antigen screening: an evidence-based report by the German Institute for Quality and Efficiency in Health Care. BJU International, 2022, 129, 280-289.	1.3	17
61	Hodgkin's Lymphoma in Adults. Deutsches ̈rzteblatt International, 2013, 110, 177-83, 183e1-30.6		16
62	Clinical practice guideline: Recommendations on the in-hospital treatment of patients with COVID-19. Deutsches ̈rzteblatt International, 2021, , .	0.6	15
63	Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma. The Cochrane Library, 2015, , CD010615.	1.5	14
64	A Systematic Review on Predictors of Working Memory Training Responsiveness in Healthy Older Adults: Methodological Challenges and Future Directions. Frontiers in Aging Neuroscience, 2020, 12, 575804.	1.7	14
65	Gender differences in health literacy of migrants: a synthesis of qualitative evidence. The Cochrane Library, 0, , .	1.5	14
66	Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. The Cochrane Library, 2013, , CD008908.	1.5	13
67	Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer). The Cochrane Library, 2018, 7, CD012556.	1.5	13
68	Interventions for improving health literacy in migrants. The Cochrane Library, 0, , .	1.5	13
69	The role of additional radiotherapy for primary central nervous system lymphoma. The Cochrane Library, 2014, , CD009211.	1.5	12
70	Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. The Cochrane Library, 2019, 9, CD012643.	1.5	12
71	Gender-Specific Aspects of Health Literacy: Perceptions of Interactions with Migrants among Health Care Providers in Germany. International Journal of Environmental Research and Public Health, 2020, 17, 2189.	1.2	12
72	Mindfulness-based interventions for substance use disorders. The Cochrane Library, 2021, 2021, CD011723.	1.5	10

#	ARTICLE	IF	CITATIONS
73	The Effect of Specialized Cancer Treatment Centers on Treatment Efficacy in Hodgkin's Lymphoma. Deutsches Ärzteblatt International, 2012, 109, 893-9.	0.6	9
74	Extension of the PRISMA 2020 statement for living systematic reviews (LSRs): protocol. F1000Research, 0, 11, 109.	0.8	9
75	Effects of Resistance Training on Motor- and Non-Motor Symptoms in Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis. Journal of Parkinson's Disease, 2022, 12, 1783-1806.	1.5	9
76	Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. , 2012, 1, CD008908.		8
77	Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma. The Cochrane Library, 2017, 4, CD007110.	1.5	8
78	Prognostic factors for change in memory test performance after memory training in healthy older adults: a systematic review and outline of statistical challenges. Diagnostic and Prognostic Research, 2020, 4, 7.	0.8	8
79	Interventions for palliative symptom control in COVID-19 patients. The Cochrane Library, 2021, 2021, CD015061.	1.5	8
80	Methods and guidance on conducting, reporting, publishing and appraising living systematic reviews: a scoping review protocol. F1000Research, 2021, 10, 802.	0.8	8
81	Therapeutic interventions for Burkitt lymphoma in children. The Cochrane Library, 2011, , CD005198.	1.5	7
82	Methodological review showed correct absolute effect size estimates for time-to-event outcomes in less than one-third of cancer-related systematic reviews. Journal of Clinical Epidemiology, 2019, 108, 1-9.	2.4	6
83	GRADE concept paper 2: Concepts for judging certainty on the calibration of prognostic models in a body of validation studies. Journal of Clinical Epidemiology, 2022, 143, 202-211.	2.4	6
84	Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. The Cochrane Library, 2022, 2022, .	1.5	6
85	A consumer network for haematological malignancies. Health Expectations, 2005, 8, 86-90.	1.1	5
86	Sixteenth Biannual Report of the Cochrane Haematological Malignancies Group: Focus on Non-Hodgkin's Lymphoma. Journal of the National Cancer Institute, 2014, 106, dju170-dju170.	3.0	5
87	Fourteenth Biannual Report of the Cochrane Haematological Malignancies Group--Focus on Autologous Stem Cell Transplantation in Hematological Malignancies. Journal of the National Cancer Institute, 2012, 104, NP-NP.	3.0	4
88	GRADE Guidelines: 29. Rating the certainty in time-to-event outcomes—Study limitations due to censoring of participants with missing data in intervention studies. Journal of Clinical Epidemiology, 2021, 129, 126-137.	2.4	4
89	Intravenous iron versus oral iron versus no iron with or without erythropoiesis-stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta-analysis. The Cochrane Library, 2022, 2022, .	1.5	4
90	Eleventh Biannual Report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin Lymphoma. Journal of the National Cancer Institute, 2010, 102, E1-E1.	3.0	3

#	ARTICLE	IF	CITATIONS
91	Thirteenth Biannual Report of the Cochrane Haematological Malignancies Group--Focus on Multiple Myeloma. Journal of the National Cancer Institute, 2011, 103, E1-E19.	3.0	3
92	Interim PET for prognosis in adults with Hodgkin lymphoma: a prognostic factor exemplar review. The Cochrane Library, 2017, , .	1.5	3
93	Nivolumab for adult individuals with Hodgkin lymphoma (an exemplar rapid review using) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50	1.5	3
94	Extension of the PRISMA 2020 statement for living systematic reviews (LSRs): protocol. F1000Research, 0, 11, 109.	0.8	2
95	Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma. Journal of Evidence-Based Medicine, 2011, 4, 142-143.	0.7	1
96	Introduction. Acta Haematologica, 2011, 125, 5-7.	0.7	1
97	Prognostic Models for Changes in Memory Performance After Memory Training in Healthy Older Adults: a Systematic Review. Journal of Cognitive Enhancement: Towards the Integration of Theory and Practice, 2021, 5, 372-385.	0.8	1
98	Clinical practice guideline: Follicular lymphoma--diagnosis, treatment, and follow-up. Deutsches Ärzteblatt International, 2021, 118, .	0.6	1
99	Evidence on the efficacy of ivermectin for COVID-19: another story of apples and oranges. BMJ Evidence-Based Medicine, 2021, , bmjebm-2021-111791.	1.7	1
100	Ninth Biannual Report of the Cochrane Haematological Malignancies Group--Focus on Hematopoietic Growth Factors. Journal of the National Cancer Institute, 2009, 101, E1-E1.	3.0	1
101	Twelfth Biannual Report of the Cochrane Haematological Malignancies Group--Focus on Tyrosine Kinase Inhibitors. Journal of the National Cancer Institute, 2011, 103, E1-E1.	3.0	0
102	BEACOPP or no BEACOPP? -- Authors' reply. Lancet Oncology, The, 2013, 14, e488-e489.	5.1	0
103	Intravenous chemotherapy versus intra-arterial chemotherapy for retinoblastoma. The Cochrane Library, 0, , .	1.5	0
104	Third Biannual Report of the Cochrane Haematological Malignancies Group. Journal of the National Cancer Institute, 2005, 97, E2.	3.0	0
105	Substantial heterogeneity found in reporting mortality in Cochrane systematic reviews and Core Outcome Sets in COMET database. Journal of Clinical Epidemiology, 2022, 145, 47-54.	2.4	0
106	Exercise for fatigue in people with cancer during and after active treatment. The Cochrane Library, 2022, 2022, .	1.5	0
107	Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation. The Cochrane Library, 2022, 2022, .	1.5	0
108	Transparently report on the process of moving from evidence to recommendation -- Authors' reply. Lancet Haematology,the, 2022, 9, e472-e473.	2.2	0